A new Tim Ferriss Show episode with Andrew Huberman moves peptide therapeutics into mainstream performance discourse, with show notes citing an FDA BPC-157 briefing document dated 2026, WADA's 2026 Prohibited List, and Eli Lilly's Phase 3 retatrutide update. The episode covers GLP-1s, growth…
# Huberman and Ferriss take peptide science to a mass audience
The Tim Ferriss Show has published an episode pairing host Tim Ferriss with Andrew Huberman under the title "Dr. Andrew Huberman: Peptides, Performance, and Protocols." The conversation moves peptide therapeutics beyond bodybuilding and into mainstream performance and health discourse, and the show notes function as a dense catalog of the regulatory and clinical forces now acting on the category. The notes cite an FDA BPC-157 briefing document dated 2026, WADA's 2026 Prohibited List , and Eli Lilly's Phase 3 retatrutide update, three items that together mark a moment in which regulators, anti-doping authorities, and trial sponsors all had something to say about the same class of molecules.
Episode timestamps show the conversation covers GLP-1 drugs, growth hormone agents, BPC-157, pinealon , epitalon , and what the notes describe as the hunt for more REM sleep. The latest timestamp listed, 01:46:37, indicates the episode runs at least that long. The sponsors are Helix Sleep, ProLon, Eight Sleep's Pod Cover 5, and Momentous creatine, a roster that ties the peptide discussion to sleep hardware, fasting diets, and supplement commerce.
Huberman is a tenured professor in the Departments of Neurobiology and Ophthalmology at Stanford University School of Medicine. He runs the Huberman Lab, and his research spans brain development, visual perception and repair from blinding diseases, the neuroscience of stress and resilience, and neural plasticity. He has published more than 75 peer-reviewed articles in journals including Nature, Science, Cell, and Neuron, and his honors include the Cogan Award, the McKnight Neuroscience Scholar Award, and the Pew Biomedical Scholar Award. He launched the Huberman Lab podcast in 2021; the notes describe it, without methodology or metrics, as the most popular health and science podcast in the world. His Instagram handle is @hubermanlab, and he is a co-founder of Scicomm Media, the company behind Huberman Lab, Perform with Dr. Andy Galpin, and the David Senra podcast. His book Protocols: An Operating Manual for the Human Body appears in the notes alongside Ferriss's The 4-Hour Body.
This is Huberman's third appearance on the show. Episode #660 covered physical and mental performance, core supplements, sexual health and fertility, sleep optimization, and psychedelics; episode #521 covered optimizing sleep, enhancing performance, reducing anxiety, increasing testosterone, and using the body to control the mind. The new episode narrows the aperture to peptides specifically, and the companion documents widen it to the entire regulatory environment around them.
The most consequential item in the notes may be the FDA BPC-157 briefing document dated 2026. BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice; it has been studied in animal models for tendon, ligament, and gut healing, but it is not an approved drug in the United States. It is widely sold as a research chemical and as a compounded product, which is exactly the market segment the FDA document signals scrutiny of. Briefing documents are the format the agency uses to lay out its analysis of a product, often to frame a regulatory decision. A document dated 2026 means the agency is formally engaging with a compound that until recently lived almost entirely outside regulated drug channels.
The notes pair that document with FDA materials on compounding and unapproved GLP-1 drugs. They cite FDA concerns with unapproved GLP-1 drugs used for weight loss, including retatrutide; FDA notices on certain bulk drug substances for compounding that may present significant safety risks; FDA compounding questions and answers; and FDA patient and consumer information on regenerative medicine therapies. The concern is not academic. When an approved drug is in shortage, compounding pharmacies may legally produce copies of it, and the GLP-1 category has produced a large market in compounded copies. Retatrutide is different in kind: it is investigational, so any compounded version of it would be unapproved by definition.
Also cited is FDA prescribing information for Egrifta tesamorelin , Mounjaro tirzepatide , Vyleesi bremelanotide , and Quviviq daridorexant . The list shows the episode's full frame. Tesamorelin is an approved growth-hormone-releasing factor analog used to reduce visceral fat in HIV-associated lipodystrophy. Tirzepatide is the approved dual GIP/GLP-1 receptor agonist for type 2 diabetes. Bremelanotide is a synthetic melanocortin receptor agonist approved for hypoactive sexual desire disorder. Daridorexant is a dual orexin receptor antagonist for insomnia, not a peptide, but its presence shows how the episode treats peptides and neuromodulators as one continuous toolkit for metabolism, sex, and sleep.
The regulatory catalog extends into psychiatry. The notes cite an FDA Complete Response Letter for midomafetamine/MDMA, alongside FDA guidance for psychedelic-drug clinical investigations. A Complete Response Letter means the agency finished its review and declined to approve the application as submitted; the notes do not state the reasons. The same document trail includes Otsuka's acquisition of Transcend Therapeutics, a commercial signal that neuroplasticity-based psychiatry is drawing pharmaceutical money, and the WADA 2026 Prohibited List. For athletes, that list is the operative boundary: a compound's legal status in sport is set by the list, not by a prescriber's rationale. The episode's pairing of the list with segments on growth hormone agents and BPC-157 gives the anti-doping frame direct contact with the molecules being discussed for performance and longevity.
Retatrutide is a single investigational molecule that agonizes three receptors: GIP, GLP-1, and glucagon. GLP-1 receptor agonism drives insulin secretion and appetite suppression; GIP and glucagon agonism add effects on energy expenditure and fat metabolism. The clinical logic is that hitting three targets in one peptide produces deeper metabolic effects than the dual agonists now on the market.
Peptide Atlas's trial registry for retatrutide holds 33 registered clinical trials. The phase breakdown on file lists six Phase 3 trials, three Phase 1 trials, and one Phase 2 trial; four trials are recruiting, four are active, and two are completed. Registered trials include:
The Peptide Atlas literature index lists 71 indexed PubMed papers on retatrutide. The recent literature includes the TRANSCEND-T2D-1 Phase 3 trial, published in The Lancet, a double-blind, randomised trial of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise PMID 42250575 , and a systematic review and meta-analysis of randomized controlled trials on the drug's effects on blood pressure and lipid levels. The show notes cite two clinical items of their own: a Phase 2 substudy in people with type 2 diabetes, published in The Lancet Diabetes & Endocrinology, examining body composition within a double-blind, parallel-group, placebo-controlled, randomised trial, and Eli Lilly's update stating that retatrutide "delivered powerful weight loss" in a Phase 3 obesity trial. The notes give the substudy's design but not its results; the Lilly statement is a company announcement, not published data.
For tirzepatide, the approved cousin of retatrutide, the registry holds 251 registered trials, with a phase breakdown that includes five Phase 2 trials, two Phase 4 trials, and one Phase 3 trial, and ten trials recruiting. The registered base has moved well beyond diabetes. Trials on file include NCT06180616 for tirzepatide in concurrent type 1 diabetes and overweight or obesity; NCT07468552 for tirzepatide in cannabis use disorder; NCT07027969 pairing metabolic surgery with atrial fibrillation elimination; NCT07609160 combining dual GLP-1/GIP agonist therapy with structured exercise to study skeletal muscle morphology, quality, and physical function; NCT06732245 testing NA-931 and tirzepatide in adults who are overweight or obese; and NCT07630454 examining tirzepatide and atrial fibrillation recurrence after catheter ablation in patients with obesity and heart failure with preserved ejection fraction. The Peptide Atlas literature index counts 188 indexed PubMed papers on tirzepatide. Its third-party lab purity tests include 18 samples tested for retatrutide, with a highest observed purity of 99.908%, and 4 samples for tirzepatide, with a highest observed purity of 99.864%.
Purity figures matter in this specific context. The FDA warnings cited in the episode concern unapproved products, and the market for research-grade peptides is where third-party identity and purity testing becomes the only quality control that exists. An untested product and the same peptide measured by a laboratory are not the same object. The episode's own warning that "no reported side effects" is a trap is another way of saying that an absence of data is not evidence of safety.
The notes do not stop at the clinic. They cite WADA's 2026 Prohibited List and attach to it a chain of anti-doping reporting. One item is a reasoned Court of Arbitration for Sport award in the nandrolone case of athlete Shelby Houlihan. Another is an NPR report about an Olympic hopeful blaming a burrito for a positive drug test, which the episode links to the "Deca burrito." Nandrolone is an anabolic steroid, and nandrolone decanoate, sold under the brand Deca-Durabolin, is one of its long-acting forms; the "Deca burrito" phrase is the episode's shorthand for the claim that contaminated meat caused a positive test. The notes also cite a headline from The Independent in which an IAAF chief describes modafinil as the drug of choice in athletics.
The Enhanced Games is the other pole. James Magnussen, the Australian swimmer, was reported by The Guardian, in a headline cited in the show notes, as saying he would "juice to the gills" to win the $1.5 million Enhanced Games prize. Reuters reported that the swimmer Gkolomeev claimed a $1 million bonus for the 50 metres freestyle at the Enhanced Games. The notes do not adjudicate any of these claims; they place them in the same document trail as the WADA list. The film Bigger, Stronger, Faster appears in the notes' product list alongside the doping material.
The juxtaposition is the point for the peptide conversation. The same molecules discussed in the episode as longevity or body-composition agents are, in the anti-doping context, regulated substances with laboratory thresholds, sanctioning systems, and international arbitration. For an athlete, the question is never whether a peptide is good for them; it is whether the peptide is on the list. That distinction is easy to lose in a conversation organized around performance and health, which is exactly why the episode's decision to surface the 2026 WADA list matters.
A substantial part of the episode is…
Peptides referenced: BPC-157, Tirzepatide, PT-141, Tesamorelin, Epithalon, Retatrutide, Growth Hormone, Pinealon.
Related reading: Zero FDA Approvals: The Translational Puzzle of Cell-Penetrating Peptides, GenScript maps three delivery routes for neoantigen vaccines, GLP-1 multi-target therapies and manufacturing near 2025 milestones, FDA Panel Backs Six Unapproved Peptides for 503A Compounding List.